RETRACTED: A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole (Publication with Expression of Concern. See vol. 16, pg. 1065, 2020) (Retracted article. See vol. 16, pg. 3129, 2020)

被引:15
作者
Hinz, Marty [1 ]
Stein, Alvin [2 ]
Uncini, Thomas [3 ]
机构
[1] Neuro Res Clin Inc, Clin Res, Cape Coral, FL 33904 USA
[2] Stein Orthoped Associates, Plantation, FL USA
[3] DBS Labs, Duluth, MN USA
关键词
depression; bipolar; serotonin; dopamine; mania; hypomania; SEROTONIN; TYROSINE;
D O I
10.2147/NDT.S14353
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: A novel method for differentiating and treating bipolar disorder cycling on the depressive pole from patients who are suffering a major depressive episode is explored in this work. To confirm the diagnosis of type 1 or type 2 bipolar disorder, the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria require that at least one manic or hypomanic episode be identified. History of one or more manic or hypomanic episodes may be impossible to obtain, representing a potential blind spot in the DSM-IV diagnostic criteria. Many bipolar patients who cycle primarily on the depressive side for many years carry a misdiagnosis of recurrent major depression, leading to treatment with antidepressants that achieve little or no relief of symptoms. This article discusses a novel approach for diagnosing and treating patients with bipolar disorder cycling on the depressive pole versus patients with recurrent major depression. Patients and methods: Patients involved in this study were formally diagnosed with recurrent major depression under DSM-IV criteria and had no medical history of mania or hypomania to support the diagnosis of bipolar disorder. All patients had suffered multiple depression treatment failures in the past, when evaluated under DSM-IV guidelines, secondary to administration of antidepressant drugs and/or serotonin with dopamine amino acid precursors. Results: This study contained 1600 patients who were diagnosed with recurrent major depression under the DSM-IV criteria. All patients had no medical history of mania or hypomania. All patients experienced no relief of depression symptoms on level 3 amino acid dosing values of the amino acid precursor dosing protocol. Of 1600 patients studied, 117 (7.3%) nonresponder patients were identified who experienced no relief of depression symptoms when the serotonin and dopamine amino acid precursor dosing values were adjusted to establish urinary serotonin and urinary dopamine levels in the Phase III therapeutic ranges. All of the 117 nonresponders who achieved no relief of depression symptoms were continued on this amino acid dosing value, and a mood-stabilizing drug was started. At this point, complete relief of depression symptoms, under evaluation with DSM-IV criteria, was noted in 114 patients within 1-5 days. With further dose adjustment of the mood-stabilizing drug, the remaining three nonresponders achieved relief of depression symptoms. Conclusion: Resolution of depression symptoms with the addition of a mood-stabilizing drug in combination with proper levels of serotonin and dopamine amino acid precursors was the basis for a clinical diagnosis of bipolar disorder cycling on the depressive pole.
引用
收藏
页码:741 / 747
页数:7
相关论文
共 12 条
[1]  
[Anonymous], 1994, Diagnostic and Statistical Manual of Mental Disorders, V4 th, P327
[2]  
Eli Lilly and Company, 2009, PROZ FLUOX HYDR PRES
[3]   METHYL MERCURY AND SELENIUM INTERACTION IN RELATION TO MOUSE KIDNEY GAMMA-GLUTAMYL-TRANSPEPTIDASE, ULTRASTRUCTURE, AND FUNCTION [J].
FAIR, PH ;
DOUGHERTY, WJ ;
BRADDON, SA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1985, 80 (01) :78-96
[4]  
Forest Labs, 2009, LEX ESC OX PRESCR
[5]  
GlaxoSmithKline, 2008, WELLB XLR BUPR HYDR
[6]  
Hinz M, 2010, OPEN ACCESS IN PRESS
[7]  
Hinz M, 2010, NEUROPSYCH DIS TREAT, V6, P387
[8]  
Hinz Marty, 2009, P467
[9]   EFFECT OF L-DOPA ON CONCENTRATIONS OF TRYPTOPHAN, TYROSINE AND SEROTONIN IN RAT BRAIN [J].
KAROBATH, M ;
DIAZ, JL ;
HUTTUNEN, MO .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1971, 14 (04) :393-&
[10]  
Spindle A, 1987, Reprod Toxicol, V1, P279, DOI 10.1016/0890-6238(87)90019-0